Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Clinical Interventions in Aging, 06/08/09
Sethi R et al. - Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood
The Aging Male, 11/13/09
Today in Endocrine...keeping you current
Receive free subspecialty "5-minute updates" via email
Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood
The Aging Male, 11/13/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Testosterone replacement in prostate cancer survivors with hypogonadal symptoms
BJU International, 11/17/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
What comes after docetaxel
Der Urologe, 11/18/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence
Journal of Clinical Oncology, 11/02/09
Article Search
Sponsor


See Latest Articles


